Breaking News, Financial News

Financial Report: Genzyme 1Q

Myozyme sales were flat at $67.4 million. In February, the company received EU approval of Myozyme produced at the 4000 L scale.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme 1Q 1Q Revenues: $1.1 billion (+4%) 1Q Earnings: $195.5 million (+35%) Comments: Myozyme sales were flat at $67.4 million. In February, the company received EU approval of Myozyme produced at the 4000 L scale. Fabrazyme sales were $122.2 million (+5%). Cerezyme sales were $296.0 million (-3%). Sales of Aldurazyme were flat at $36.8 million. Renvela and Renagel sales were $170.6 million (+1). Sales of Thyrogen were up 15% to $38.8 million. Revenue from the company’s Hematologic On...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters